TCM
EPIX

Tang Capital Management’s ESSA Pharma EPIX Stock Holding History

Tang Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,300,000
Closed -$7.31M – 200
2025
Q2 		$7.31M Hold
4,300,000
– – 0.37% 66
2025
Q1 		$6.79M Hold
4,300,000
– – 0.38% 62
2024
Q4 		$7.7M Buy
+4,300,000
New +$13.7M 0.51% 53

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Tang Capital Management's EPIX Position: Q3 2025 in Review

Tang Capital Management sold out of ESSA Pharma (EPIX) in Q3 2025, closing a stake of 4,300,000 shares — an estimated $7.31M sold.

Tang Capital Management first reported a position in EPIX in Q4 2024 and held it in 3 quarters. The position peaked at $7.7M in Q4 2024. 32 funds tracked by Wall St. Rank hold EPIX as of Q3 2025.

  • Tang Capital Management reported no remaining ESSA Pharma position as of Q3 2025 after selling out during the quarter.
  • Tang Capital Management sold 4,300,000 ESSA Pharma shares in Q3 2025, an estimated $7.31M.
  • Tang Capital Management first reported a position in ESSA Pharma in Q4 2024 and held it in 3 quarters.
  • Tang Capital Management's ESSA Pharma position peaked at $7.7M in Q4 2024.
  • 32 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2025.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.